Bidness ETC - Novartis Stock Update For Current Quarter

Novartis stocks are estimated an earning per share of $1.12 for the current quarter.

Novartis AG is a prominent name in the world of healthcare providing health solutions globally. The company’s network is global having the status of a multinational firm whose expertise lies in marketing, research, manufacturing and development in a variety of medical products for healthcare purposes. The company has a diversified portfolio of products in services where it caters to medicines, animal health products, preventive vaccines, eye care, diagnostic tools, generic pharmaceuticals that are cost effective etc.

There are five core operating segments of the company: pharmaceuticals which comprises of patent protected medicine prescription, Alcon that deals with surgical, vision care products and ophthalmic pharmaceutical, diagnostic and vaccines that deals with blood testing procedures and human vaccine development, consumer health that provides over the counter medicines along with Animal Health.

The company in 2011 acquired a non controlling interest in Alcon which was again a major breakthrough for them.

Analysts at Wall Street expect that the first quarter earnings per share for Novartis stocks is estimated to be $1.12 for the current quarter. The digits have been derived from the average estimations made by the sell-side research organization dealing with the stocks. Recent NVS reported their earnings per share (EPS) which compounded to $1.33 for the first quarter of the fiscal year of 2015. This highlights that the digits are almost 0.21 where analysts estimate an 18.75 percent difference.

On an average, all the analysts who have kept eyes on Novartis stock price have estimated a price target of $108.166. this is said to be mean estimates of the three companies that are watching this stock closely. This is said to be the latest update in terms of Novartis stock price target.

In general the broker recommendation is basically an average taken of individual ratings that are provided by analysts allowing them to come up with Consensus Analyst Rating for each and every stock. Usually, there are ratings given for each stock from 1 to 5 where 1 means a strong BUY whereas 5 means a strong SELL.

Hence, Novartis at this point of time has 1.75 rating given by three sell-side analysts. A part of this group is a sell-side firm that expects a substantial upside on the stock price which is said to turn to $115 in a year’s time. The analyst who is conservative about the stock has given an estimated price target of $103.5 in a year’s time.

Novartis (NVS) stocks are currently extremely bullish and even those conservative about the stock have given a fairly good price target.

Bidness Etc - Novartis Accused Of Sexual Discrimination

Novartis sexually discriminates female workers by giving them fewer growth opportunities

Novartis, the popular pharmaceutical company is on an inconsistent stage now where a lawsuit has been filed against them by their former employees. According to the lawsuit, a class action will also be taken against the company.

The company has been accused of discriminating against women. The women employees at Novartis claimed that on a regular basis they were denied a pay scale on par with the men in the organization. Moreover, they were not given any promotion or monetary rewards on their performance.

This is not the first time when Novartis is found to be involved in such an activity. Five years ago the company was accused of gender discrimination by some of the female sales workers at the organization. The company was liable to pay an amount of $152.5 million back then. Novartis has now ignited a similar controversy all over again.

Basically, this lawsuit has been filed by two ladies who primarily worked on the Alcon eye-care products segment. They accused the company of many the environment dominated by the opposite gender and also accused them of making the environment fairly hostile to the women working in the office. Moreover, they also limited the opportunities of growth for women employees restricting them from opting for executive positions. The case has been filed in the district of New York.

According to the petition filed. At Novartis, less than 15% of the women have occupied position as the senior executive management which surely indicates that the company is involved in gender discrimination. Moreover, women are never given their destined rights even if they are capable and have the talent.

Even when the performances of workers are evaluated at Novartis, women are downgraded in terms of performance. When the performance reaches the executive board, they usually tend to manipulate it since the executive leadership is filled with male members.

However, Novartis AG (NYSE:NVS) defends itself by saying that it ensures a healthy working environment and does not discriminate on the basis of the gender. The spokeswoman at Novartis stated: “deeply committed to equal employment opportunity for all employees and to preventing discrimination.” Moreover, they also accused the employees who have filed the lawsuit to be involved in ill activities that violated the company’s code of conduct. They were terminated due to the “serious violations”.

Hence, in a nutshell, Novartis is again encountering a similar issue which can cause them to lose a hefty amount. It is too early to predict whether the company was involved in discrimination